|
Brand Name Manufacturers |
Estrovis by Parke-Davis |
|
Generic Manufacturers |
None |
|
Pharmacology |
3-cyclopentylether of ethinyl estradiol. Acts on receptors apparently the same as endogenous estrogen. |
|
Delivery |
Oral 0.1mg tablets |
|
Typical dosage |
Pre-op ? |
|
Availability |
Approved by U.S. FDA |
|
Average Wholesale Price |
$141.70/100 |
|
Indications |
Estrogen replacement therapy in females |
|
Contraindications |
Active blood clotting disorders. History of blood clotting disorder in association with estrogen therapy. Known or suspected breast cancer. Known or suspected estrogen-dependent tumors. |
|
Adverse reactions |
CNS Dizziness. Headache. Mental depression. Migraine. Spasms of limb and facial muscles. Eyes Intolerance to contact lenses. Steepening of corneal curvature. Gastrointestinal Abdominal cramps. Bloating. Cholestatic jaundice. Nausea. Vomiting. Skin Blood eruptions from skin. Blotchy skin pigmentation. Increase of body and facial hair. Loss of scalp hair. Red skin patches from capillary congestion. Other Blood clotting disorders. Breast and liver tumors. Elevated blood pressure. Fluid retention. Gall bladder disease. Increased calcium level in blood. Increased sensitivity to light. Reduced carbohydrate and glucose tolerance. |
|
Comments |